| 2020 | 2021 | 2022 | 2023 (projected) | Revenues USD | 11.8 M | 48.04 M | 64.36 M | 69.44 M | Revenues | 11.8 M | 48.04 M | 64.36 M | 69.44 M |
Ownership Breakdown
| Retail Investors23.54% | Insiders9.79% | Institutions66.67% |
| Retail Investors | 23.54 | |
| Insiders | 9.79 | |
| Institutions | 66.67 |
Will UroGen Pharma (USA Stocks:URGN) turn things around in September?
 | By Raphi Shpitalnik | Macroaxis Story |
UroGen Pharma (URGN.US), a key player in the healthcare sector, specifically within the biotechnology and pharmaceuticals industry, has been under the radar of investors for a while now. The company, with an enterprise value of 543.3M, has been operating at a loss with a net income from continuing operations standing at 109.8M and an operating margin of -1.16. Despite the negative return on assets of -0.35 and return on equity of -14.81, the company has managed to generate an interest income of 938K. The Wall Street target price for the stock is 39.25, while the company's valuation market value and real value stand at 18.99 and 22.95 respectively. As we step into September, the question arises - is UroGen Pharma poised for a bullish reversal? The Price to Sales Ratio of UroGen Pharma is currently quite stable compared to the previous year. Last year, UroGen Pharma reported a Price to Sales Ratio of 3.14. As of August 3rd, 2023, the Return on Average Equity is projected to increase to 2.25, while the Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) are expected to decrease to -$105.5 million.
Given the excitement among millennials about the biotechnology sector, it's appropriate to take a detailed look at UroGen Pharma. This article will examine the stock closely, including the recent sentiment expressed by insiders. The aim is to highlight some fundamental factors that affect UroGen Pharma's products and services. Additionally, this article will shed light on how these factors may influence the investment outlook for UroGen Pharma in September.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
UroGen Pharma (URGN) is a domestic biotechnology company with a market capitalization of 477.9M. Despite a negative income before tax of 108M and a net interest income loss of 7.4M, there are several indicators that suggest a potential bullish reversal for the company in September. The company's Total Risk Alpha of 0.46 and Sortino Ratio of 0.29 suggest that the company's returns could potentially outweigh its risks. Furthermore, the company's EPS estimate for the current year is a loss of 3.89, but the EPS estimate for the next quarter is a significantly lower loss of 1.23. This suggests that the company's financial performance could improve in the near future. Despite a price percent change of -6.45, the company's last price was 18.99, which is relatively close to its high price of 20.89. This suggests that the company's stock price could potentially increase in the future.
Detailed assessment
Over 67.0% of UroGen Pharma's outstanding shares are owned by institutional investors. The institutional ownership of UroGen Pharma pertains to the portion of UroGen Pharma's equity held by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage funds on behalf of others. For our latest analysis of UroGen, including its current ownership diagnostics, please check out our most recent report.The performance of UroGen Pharma in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence UroGen Pharma's stock prices. When investing in UroGen Pharma, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, UroGen Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as UroGen Pharma carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.How important is UroGen Pharma's Liquidity
UroGen Pharma financial leverage refers to using borrowed capital as a funding source to finance UroGen Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. UroGen Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to UroGen Pharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of UroGen Pharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between UroGen Pharma's total debt and its cash.
What do experts say about UroGen?
Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
Analysis ConsensusWhat is driving UroGen Pharma Investor Appetite?
UroGen Pharma maintains a total of 23.45 Million outstanding shares. Over half of UroGen Pharma outstanding shares are owned by institutional holders. These institutional holders are typically referred to corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutional investors. class="underlinedLink" href="/invest/ratio/URGN/Shares-Owned-by-Institutions">institutions are subject to different rules and regulation than regular investors in UroGen Pharma. Please watch out for any change in the institutional holdings of UroGen Pharma as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
UroGen Pharma (URGN.US), a player in the Biotechnology industry, has been making waves in the Health Care sector. Despite a challenging year, the company's market capitalization stands at a respectable $477.87M, with an enterprise value of $543.3M.The firm's revenue has been reported at $64.36M, contributing to a gross profit of $56.7M. However, UroGen's financial health is not without its concerns. The company reported a net income loss of $109.8M, with an operating income loss of $79M. Its total debt stands at $99.12M, against net assets of $136.24M, indicating a substantial financial burden. Furthermore, the company's EPS estimate for the current year is a loss of $3.89, and the EPS estimate for the next quarter is a loss of $1.23. Despite these challenges, UroGen's stock is held in high regard by institutions, with 66.67% of shares owned by them. The Wall Street target price for the stock is $39.25, indicating potential for growth. The company's risk-adjusted performance is 0.0763, suggesting that it may be a viable investment option for risk-tolerant investors. In conclusion, while UroGen Pharma has its financial hurdles to overcome, there are signs that a bullish reversal may be on the horizon for this NASDAQ-listed company. With a strong institutional backing and a promising target price, UroGen may indeed be poised for a positive turnaround in September. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of UroGen Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.